Clinical trials: COVID19 ARDS
COVID-19
Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial
This is a a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of…
- Trial name
- DART (NCT04482621)
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2
Evaluation of Sedation in COVID-19 ARDS
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients.
- Conditions
- Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2, Hypnotics and Sedatives, Pulmonary Ventilation
- Trial name
- NCT04667936
- Testing
- Treatment group
- Where
- Germany
- Volunteers
- 114 people
- Sponsor
- Goethe University
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
ARDS, Human, COVID-19 Acute Respiratory Distress Syndrome
Characterization of the microVAScular Dysfunction in Covid-19 ARDS
The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS.
- Trial name
- VASCOV (NCT05074758)
- Testing
- alveolar dead-space quantification, Coagulation activation and impaired fibrinolysis explorations, Endothelial activation / endothelial senescence
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumonia, Viral
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
Severe Acute Respiratory Syndrome (SARS) SARS-CoV-2, name of the Coronavirus Group of international Committee on taxonomy of viruses, is an emerging virus from the family of coronaviridae, responsible for the COVID-19 pandemic.
- Trial name
- PULCO-19 (NCT04422613)
- Testing
- pulmonary anomalies 4 months after documented COVID-19 pneumonia
- Where
- France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Toulouse
COVID-19, Acute Respiratory Distress Syndrome
Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery
An informational evaluation of COVID-19 patients who receive low-level laser therapy in addition to a normal regimen of treatment for symptoms associate with COVID-19.
- Trial name
- NCT05258617
- Testing
- LLLT Photobiomodulation
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ward Photonics LLC
COVID-19 Acute Respiratory Distress Syndrome
Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19
The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on therapy on maximal medical treatment versus maximal medical treatment alone in treating moderate-to-severe ARDS due to SARS-CoV-2.
- Trial name
- MINECRAFT (NCT04977960)
- Testing
- Potassium Canrenoate
- Volunteers
- 180 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Covid-19
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
- Trial name
- NCT04522817
- Testing
- CLBS119
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
Respiratory Distress Syndrome
The ECOVITA Study - Validation of LUS Score in SARS-CoV-2 Disease, i.e COVID-19
Lung Ultrasound (LUS) has been revealing an extremely useful tool to identify and monitor complications from Sars-COV-2 disease.
- Trial name
- ECOVITA (NCT04871685)
- Testing
- lung ultrasound
- Where
- Italy
- Volunteers
- 950 people
- Sponsor
- University of Campania Luigi Vanvitelli
Coronavirus, Covid19
Impact of Aerosol Box Use on Healthcare Provider Contamination
Aerosol Generating Medical Procedures (AGMP) are procedures that have the potential to create tiny particles suspended in the air. These particles can contain germs such as viruses.
- Conditions
- Coronavirus, Covid19, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT04880668
- Testing
- Aerosol Box (Splashguard)
- Where
- 4 sites in United States, Canada
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- KidSIM Simulation Program
Covid19, Sars-CoV-2 Infection
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date.
- Conditions
- Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
- Trial name
- NCT04715360
- Testing
- autologous activated platelet-rich plasma, Avigan
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Hayandra Peduli Foundation
Sars-CoV2, ARDS
Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection
The purpose of this study is to evaluate if a postural recruitment maneuver (PRM) improves the aeration and distribution of lung ventilation in patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19…
- Trial name
- NCT04475068
- Testing
- Lateral Position (left and right lateral decubitus)
- Where
- Peru
- Volunteers
- 15 people
- Sponsor
- Hospital Nacional Edgardo Rebagliati Martins
COVID-19 Infection
Clazakizumab vs. Placebo - COVID-19 Infection
The purpose of this study is to investigate the effectiveness and safety of treatment with clazakizumab compared to a placebo (inactive substance).
- Trial name
- NCT04494724
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Methodist Hospital Research Institute
COVID-19 Acute Respiratory Distress Syndrome
PRactice of Ventilation and Adjunctive Therapies in COVID-19 Patients.
PRactice of Ventilation and Adjunctive Therapies in COVID-19 Patients. An observational study of ventilation practice and adjunctive therapies in critically ill, invasively ventilated COVID-19 patients during the first and second…
- Trial name
- PRoVAcT-COVID (NCT05954351)
- Where
- Netherlands
- Volunteers
- 2,465 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Respiratory Distress Syndrome
Prone Positioning vs. Prone Positioning and NO Inhalation in COVID-19 ARDS.
The investigators aim to investigate the effects of prone positioning and prone positioning with NO inhalation for COVID-19 patients with ARDS.
- Trial name
- NCT05715788
- Testing
- Nitric oxide, prone positioning
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
ARDS, COVID19
Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS
The 2020 pandemic of the coronavirus (SARS-CoV2) has lead to an increase in ARDS cases requiring invasive mechanical ventilation in the ICU (Intensive Care Unit).
- Trial name
- APRV-COVID19 (NCT04386369)
- Testing
- Airway pressure release ventilation
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Central Hospital, Nancy, France
Covid19, Severe Acute Respiratory Syndrome
Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19
Pilot clinical trial, with a marketed drug -natural component of human plasma-, not approved for this indication, single-center, exploratory, open, randomized, controlled, to study the efficacy and safety of human Antithrombin in…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, Distress Respiratory Syndrome
- Trial name
- NCT04745442
- Testing
- Antithrombin + best available treatment, Best available treatment
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Acute Respiratory Distress Syndrome, COVID-19
Polyvalent Immunoglobulin in COVID-19 Related ARds
As of 30/03/2020, 715600 people have been infected with COVID-19 worldwide and 35500 people died, essentially due to respiratory distress syndrome (ARDS) complicated in 25% of the with acute renal failure.
- Trial name
- ICAR (NCT04350580)
- Testing
- Human immunoglobulin
- Where
- 42 sites in France
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier St Anne
Covid19-associated ARDS, Covid19
A First-in-Human Study of AV-001 in Healthy Subjects
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects.
- Conditions
- Covid19-associated ARDS, Covid19, ARDS
- Trial name
- NCT04737486
- Testing
- AV-001
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vasomune Therapeutics, Inc.
SARS-CoV 2, COVID
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or…
- Conditions
- SARS-CoV 2, COVID, ARDS, ALI
- Trial name
- AVICOVID-2 (NCT04360096)
- Testing
- ZYESAMI™ (aviptadil acetate)
- Where
- 13 sites in United States
- Volunteers
- 144 people
- Sponsor
- APR Applied Pharma Research s.a.